2 results
Approved WMORecruiting
To evaluate, in patients with end stage knee osteoarthritis, the in vivo disease (tissue structure) modifying activity of celecoxib, as a selective COX-2 inhibitor, in addition to its inflammation regulatory properties, compared to naproxen as a…
Approved WMORecruiting
Primary Safety Objective: • To evaluate initial safety of UCon for treatment of OAB symptoms in a home setting.Secondary Safety Objective• To demonstrate that subjects using UCon do not experience an unacceptable amount of device- or procedure…